Respiratory System Neoplasm

The goal of this study, was to find the predictive effect of ERCC1, RRM1 and LRP expression on the effectiveness of gemcitabine concomitant with nedaplatin, as a form of treatment, with patients who h… (full text at CIViC)

PMID 25227833 · Qiu et al., 2014 · Open in CIViC

Expression level of ERCC1 was evaluated in 61 NSCLC samples with RT-qPCR. Kaplan-Meier analysis showed that low expression of ERCC1 was associated with longer median survival time (17.3 versus 10.9 mo… (full text at CIViC)

PMID 16980606 · Ceppi et al., 2006 · Open in CIViC

In this review article, the median survival of non-small cell lung cancer patients with low levels of ERCC1, treated with platinum-based therapies was significantly prolonged as compared to those with… (full text at CIViC)

PMID 16807441 · Rosell et al., 2006 · Open in CIViC

The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three prev… (full text at CIViC)

PMID 19470925 · Gandara et al., 2009 · Open in CIViC

In a retrospective pan-cancer ICI-treated cohort from MSKCC (cohort 3, n = 1661), ERCC2/ERCC3/ERCC4/ERCC5-mutated tumors demonstrated improved OS vs ERCC-WT tumors (HR 0.54, 95% CI 0.42-0.70; p < 0.00… (full text at CIViC)

PMID 37626083 · Chen et al., 2023 · Open in CIViC

Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoter… (full text at CIViC)

PMID 26894620 · Bauer et al., 2017 · Open in CIViC

EGFR activity was markedly decreased during the evolution of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, with a concomitant increase of ERRFI1(Mig6), a negative regulator of EGFR… (full text at CIViC)

PMID 23935914 · Chang et al., 2013 · Open in CIViC

Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advance… (full text at CIViC)

PMID 26893365 · Hong et al., 2016 · Open in CIViC

In vitro studies in KRAS G12C lung cancer cells (CALU1) showed that overexpression of ETV1 modulated resistance to trametinib.

PMID 28178529 · Wang et al., 2017 · Open in CIViC

In vitro studies in KRAS G12C lung cancer cells (CALU1) showed that overexpression of ETV4 modulated resistance to trametinib.

PMID 28178529 · Wang et al., 2017 · Open in CIViC

In vitro studies in KRAS G12C lung cancer cells (CALU1) showed that overexpression of ETV5 modulated resistance to trametinib.

PMID 28178529 · Wang et al., 2017 · Open in CIViC

In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates w… (full text at CIViC)

PMID 23182986 · Kim et al., 2013 · Open in CIViC

Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metas… (full text at CIViC)

PMID 25433983 · Jiang et al., 2015 · Open in CIViC

Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC. Patient was treated with 400 mg pazopanib twice a day. CT taken four and… (full text at CIViC)

PMID 24302556 · Malchers et al., 2014 · Open in CIViC

Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition. The authors suggested that FG… (full text at CIViC)

PMID 24771645 · Wynes et al., 2014 · Open in CIViC

Study of FGFR1 inhibitor AZD4547 in NSCLC xenograft models. FGFR1-amplified models that overexpress FGFR1 (detected by IHC) were strongly inhibited by 25mg/kg AZH4547 (P≤0.0001). Another FGFR1-ampli… (full text at CIViC)

PMID 23082000 · Zhang et al., 2012 · Open in CIViC

Rogaratinib (BAY 1163877) was tested in cell line- and patient-derived models of lung cancer. DMS‐114 models, which have FGFR1 amplification and overexpression, had significantly decreased tumor volu… (full text at CIViC)

PMID 30807645 · Grünewald et al., 2019 · Open in CIViC

FGFR2 C491S was identified as selectively conferring futibatinib resistance in FGFR-dependent NCI-H1581 cells and was independently validated by drug-treated cell-viability and FGFR phosphorylation ex… (full text at CIViC)

PMID 41361008 · Tangermann et al., 2025 · Open in CIViC

NIH-3T3 cells with the FGFR2 K660E kinase domain mutation demonstrated an increase in colony formation relative to wild-type in an anchorage-independence assay, which was lost with the introduction of… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

It is clear that patients with FGFR2/Plcγ1/Grb2 relative concentrations as: high/high/low have the poorest prognosis whilst those having FGFR2/Plcγ1/Grb2 as: low/low/high drastically enhances the prog… (full text at CIViC)

PMID 26693065 · Timsah et al., 2015 · Open in CIViC

NIH-3T3 cells with the FGFR2 S320C extracellular domain mutation demonstrated an increase in colony formation in an anchorage-independence assay, which was lost with the introduction of AP24534, BGJ39… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In FGFR-dependent NCI-H1581 lung cancer cells, FGFR2 V564G was identified by saturation mutational scanning as a pemigatinib-resistance mutation and was independently validated by cell-viability and p… (full text at CIViC)

PMID 41361008 · Tangermann et al., 2025 · Open in CIViC

NIH-3T3 cells with the FGFR2 W290C extracellular domain mutation demonstrated an increase in colony formation in an anchorage independent growth assay, which was lost with the introduction of AP24534,… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

DNA was extracted from the paraffin-embedded tissues of 86 NSCLC tissues. 72 of the samples were tested for FGFR3 alterations in exons 7, 10, and 15 by sequencing, and two showed point mutations causi… (full text at CIViC)

PMID 36794128 · Lin et al., 2023 · Open in CIViC

FGFR3 G691R mutations were found in ~5.5% of lung adenocarcinoma patients using NGS and mass-spectrometry. The mutation was further found to transform NIH-3T3 cells and form tumors upon xenotransplant… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

NIH-3T3 cells with the FGFR3 R248C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by treatm… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR3 S249C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by the tr… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In this study, 363 lung adenocarcinoma tumors of Indian origin were analyzed using targeted next-generation sequencing and mass spectrometry genotyping, and FGFR3 mutations were identified in 20 tumor… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

In a set of 116 NSCLC tissues, 72 were tested for alterations in exons 7, 10, and 15 by sequencing. Sequencing of normal control tissue was not described. FGFR3 expression was also tested by IHC. From… (full text at CIViC)

PMID 36794128 · Lin et al., 2023 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.

PMID 22541434 · Kumar et al., 2012 · Open in CIViC

The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smo… (full text at CIViC)

PMID 24758907 · Hong et al., 2014 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

Inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner. Cells transformed with mutant HRAS isoforms Q61L, Q61R and G12V demonstrated equal sensitivity to… (full text at CIViC)

PMID 26544513 · Kiessling et al., 2015 · Open in CIViC

Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity. IGF1R expressio… (full text at CIViC)

PMID 23619944 · Peled et al., 2013 · Open in CIViC

Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance. Overexpr… (full text at CIViC)

PMID 22333600 · Shimokawa et al., 2012 · Open in CIViC

Comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti-PD-L1 therapy. Two activating… (full text at CIViC)

PMID 26014096 · Van Allen et al., 2015 · Open in CIViC

Comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti-PD-L1 therapy. Two activating… (full text at CIViC)

PMID 26014096 · Van Allen et al., 2015 · Open in CIViC